Skip to main content
. 2021 Jul 6;118(28):e2026403118. doi: 10.1073/pnas.2026403118

Fig. 1.

Fig. 1.

Pharmacological screening of FDA-approved drugs using a Drosophila follicle rupture assay. (A) A schematic of the drug screening using the ex vivo follicle rupture assay. Mature follicles with an intact follicle-cell layer (marked red) were isolated from Drosophila ovaries and pretreated with DMSO or drugs for 15 min before adding OA at 20 μM for 3 h. (A, Right) Representative images showing follicles after a 3-h OA culture. Ruptured follicles are marked with white arrowheads. (B) The primary screen result of 1,172 FDA-approved drugs. The y axis is the log2-transformed fold change of rupture rates between the individual drug groups and DMSO groups. (C) The validation result of 75 selected drugs identified from the primary screen. The red bars are drugs with log2FC <−1 and the purple bars are drugs with −1< log2FC <−0.75. (D) The categories of 16 identified candidate drugs. Also see SI Appendix, Table S1.